Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a ...

Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...

Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the treatment in a ...

General Motors has released an updated fix for a fuel injector flow rate issue affecting certain units of the Chevy Trax crossover, revising an earlier Service Update for the issue with a more ...

High mileage on a 6.6 Duramax is less about a single scary number on the odometer and more about how that number lines up with the engine’s design, maintenance history, and known weak spots. The same ...

Novo Nordisk faces management missteps, pipeline concerns, and aggressive M&A moves, making its stock less attractive compared to peers. LLY is favored for its strong management, robust obesity ...

In the last decade, Eli Lilly stock (NYSE: LLY) has returned $47 billion to its shareholders via dividends and buybacks. This shareholder-centric approach has delivered solid results in 2025, with the ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company (NYSE:LLY) launched the easy-to-use injector pen of its weight-loss and diabetes ...